GlaxoSmithKline Integrates Cancer Discovery, Development In “GSK Oncology” Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
The move mirrors actions of other major pharmas, such as Pfizer and Novartis.
You may also be interested in...
GSK’s Witty Looks To Biotech Model In R&D Retool; Mini Labs Will Bid For Project Funding
Planned units include five to 80 scientists, operate within the CEDDs program.
Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try
CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.